Open Access

Prediction of a time-to-event trait using genome wide SNP data

  • Jinseog Kim1,
  • Insuk Sohn2,
  • Dae-Soon Son3,
  • Dong Hwan Kim4,
  • Taejin Ahn3 and
  • Sin-Ho Jung5Email author
Contributed equally
BMC Bioinformatics201314:58

DOI: 10.1186/1471-2105-14-58

Received: 30 October 2012

Accepted: 12 February 2013

Published: 19 February 2013

Abstract

Background

A popular objective of many high-throughput genome projects is to discover various genomic markers associated with traits and develop statistical models to predict traits of future patients based on marker values.

Results

In this paper, we present a prediction method for time-to-event traits using genome-wide single-nucleotide polymorphisms (SNPs). We also propose a MaxTest associating between a time-to-event trait and a SNP accounting for its possible genetic models. The proposed MaxTest can help screen out nonprognostic SNPs and identify genetic models of prognostic SNPs. The performance of the proposed method is evaluated through simulations.

Conclusions

In conjunction with the MaxTest, the proposed method provides more parsimonious prediction models but includes more prognostic SNPs than some naive prediction methods. The proposed method is demonstrated with real GWAS data.

Background

A genome-wide association study (GWAS) involves an examination of the entire genome, typically single-nucleotide polymorphisms (SNPs), of different individuals to determine whether any variant is associated with a particular clinical outcome. Many researchers have considered the design and analysis of GWASs with respect to binary clinical outcomes such as case/control or response/non-response ones [1-5].

In clinical cancer research, the primary endpoint of interest is usually a time-to-event trait subject to censoring. In CALGB 80803, for example, germline DNAs are collected, together with time to progression and overall survival data, from 352 advanced pancreatic cancer patients. One objective of an SNP correlative study is to discover SNP markers that are correlated with such time-to-event endpoints.

One of the first objectives of a statistical analysis in a GWAS is the discovery of SNP markers that are associated with a particular trait. The major statistical issue in marker discovery is multiple testing to avoid enlarged type I error probability due to the large number of univariate tests [6, 7]. Each prognostic SNP has two or three possible outcomes depending on its genetic model, and the efficiency of a statistical method in associating it with a trait is maximized when the true genetic model is known. For most SNPs, however, the true genetic model is unknown. To identify the true genetic model of each SNP and optimize the association analysis, many researchers have considered some candidate genetic models for a given trait and derived a null distribution of the maximum of test statistics specific to individual genetic models [8, 9]. This test is referred to as the MaxTest. These methods have been developed for binary traits such as case/control or response/non-response ones. We develop a MaxTest to identify the genetic model of each SNP when the trait is a survival endpoint, e.g., the time to tumor progression or death.

Another major objective of a GWAS is to predict a trait of interest by using SNPs. Prediction methods using microarray data have been widely investigated [10-12], but cannot be directly applied to SNP-based predictions. The number of SNP markers in genome-wide SNP data far exceeds that of gene markers (or probes) in microarray data, e.g., 1M vs. 20K. In addition, although gene expression data in microarray studies are continuous, genome-wide SNP data are discrete, taking only three different values at most and showing different values depending on the genetic model.

This paper presents a method for predicting a survival outcome that uses genome-wide SNP data but can be easily modified for any type of trait, including binary or continuous outcomes. The proposed method uses the gradient lasso method [13], which has been developed for microarray data. Some investigators fit a prediction model while ignoring the genetic model of each SNP [14]. We also propose a MaxTest associating between a time-to-event trait and a SNP accounting for its possible genetic model and identifies the genetic model of each candidate prognostic SNP by using the proposed MaxTest before fitting a prediction model. The simulation results show that this procedure improves prediction efficiency and prognostic power. For computational efficiency, nonsignificant SNPs are excluded using the MaxTest before starting the gradient lasso. For the facilitation of the proposed MaxTest and prediction method, glcoxphSNP R packages (http://datamining.dongguk.ac.kr/Rlib/glcoxphSNP) are provided.

Methods

Genetic Models of SNPs

Suppose that the genotype for an SNP is encoded as AA, AB, or BB. Let g denote the number of copies of the B allele. That is, g=0, 1 or 2 if the genotype is AA, AB, or BB, respectively. Let λ g (t) denote the hazard function of genotype g. Without loss of generality, assume that B is the risk allele in the sense that having B increases the risk of an event. More specifically, assume that λ0(t)≤λ1(t)≤λ2(t) for all t≥0. (Note that for some specific diseases, this may not be an appropriate genetic model.) We now consider the following three popular genetic models:

  • Recessive model: λ0(t)=λ1(t)<λ2(t).

  • Dominant model: λ0(t)<λ1(t)=λ2(t).

  • Multiplicative model: λ2(t)/λ1(t)=λ1(t)/λ0(t), or equivalently λ1(t)=γ λ0(t) and λ2(t)=γ2λ0(t) for γ>0.

For a chosen score c g , we consider a proportional hazard model (PHM), λ g (t)=λ0(t) exp(β c g ). Then Cox’s partial maximum likelihood test has optimal power with (c0,c1,c2)=(0,0,1) for a recessive model, (0,1,1) for a dominant model, and (0,1,2) for a multiplicative model [15]. Note that the PHM is invariant to the linear transformation of the covariate (c0,c1,c2).

MaxTest

Suppose that we want to test whether an SNP is associated with a given clinical outcome. The test statistic is dependent on the true genetic model of the SNP. At the time of testing, however, we usually have no knowledge of the true genetic model. In this case, a naive approach is to conduct all statistical tests by assuming different genetic models and choose the lowest p-value as the measurement of the association. This approach can lead to an enlarged Type I error because of multiple tests. To adjust for multiple tests, investigators have proposed a method considering the maximum of test statistics with respect to all candidate genetic models under consideration, namely the MaxTest.

Many studies have considered the MaxTest for binary clinical outcomes. Zheng et al. [8] propose a robust ranking method when the underlying genetic model is unknown, namely the MAX-rank test. Conneely and Boehnke [16] propose a method for computing p-values that adjusts for correlated tests and show that the method can improve the accuracy of permutation tests with greater computational efficiency. Li et al. [17] propose a method for approximating the p-value for the MaxTest with or without covariates adjusted for, namely the P-rank test. Li et al. [9] compare the results of the MAX-rank and P-rank tests. Hoggart et al. [18] formulate the problem as variable selection in a logistic regression analysis including a covariate for each SNP and find the posterior mode for shrinkage priors based on a stochastic search on a penalized likelihood function.

We propose a MaxTest for survival endpoints. Here we assign numeric scores to three genotypes based on their genetic model: (c0,c1,c2)=(0,0,1) for a recessive model, (c0,c1,c2)=(0,1,1) for a dominant model, and (c0,c1,c2)=(0,1,2) for a multiplicative model. For a given score c g assigned to the genotype g (=0,1,2) of an SNP, we consider the Cox propotional hazard model,
λ g ( t ) = λ 0 ( t ) exp ( β c g ) .
For patient i (=1,....,n), let T i and C i denote the survival and censoring times, respectively. We observe that X i = min(T i ,C i ) and δ i =I(T i C i ), where I(·) indicates the indicator function. In addition, for t≥0, let Y i (t)=I(X i t) and N i (t)=δ i I(X i t) denote the at-risk and event processes, respectively. For a given score, we set z i =c g if patient i has genotype g. Let s k ( t ) = i = 1 n z i k Y i ( t ) , k=0,1,2. Then, the partial score test statistic by Cox [19],
W = n 1 / 2 i = 1 n 0 { z i s 1 ( t ) / s 0 ( t ) } d N i ( t )
is asymptotically normal with mean 0 and variance that can be consistently estimated by
σ ̂ 2 = n 1 i = 1 n 0 s 2 ( t ) s 0 ( t ) s 1 2 ( t ) s 0 2 ( t ) d N i ( t )

under H0:λ0(t)=λ1(t)=λ2(t) [see, e.g., [20]].

By combining the statistics with respect to the three candidate genetic models, we can derive a MaxTest statistic. Let W l and σ ̂ l 2 denote the test statistic and the variance estimator with respect to genetic model l (=1,2,3). Then we can define the proposed MaxTest as Q= max(|T1|,|T2|,|T3|), where T l = W l / σ ̂ l . Under H0, σ l l = cov ( W l , W l ) is consistently estimated by
σ ̂ l l = n 1 i = 1 n 0 z li s l 1 ( t ) s l 0 ( t ) z l i s l 1 ( t ) s l 0 ( t ) Y i ( t ) Y ( t ) dN ( t )

where z l i and s l k (t) denote z i and s k (t), respectively, for genetic model l; Y ( t ) = i = 1 n Y i ( t ) , N ( t ) = i = 1 n N i ( t ) . Let Σ ̂ = ( ρ ̂ l l ) 1 l , l 3 , where ρ ̂ l l = σ ̂ l l / σ ̂ l σ ̂ l . Then we can obtain the critical value of Q by a numerical method or a simulation method from the N ( 0 , Σ ̂ ) distribution. This is a survival trait counterpart for the MaxTest with a binary trait, as discussed in several studies [9, 21].

We can construct an alternative test based on the quadratic form W 2 = S T Σ ̂ 1 S , where S=(T1,T2,T3) T . In addition to recessive, dominant, and multiplicative genetic models, we can consider other models to develop a test statistic to measure the relationship between an SNP and a survival trait. For example, we may consider the long-rank test based on the one-way ANOVA in [22] or the test based on the Wilcoxon Rank-Sum test in [23], which require no specific genetic model assumptions. In particular, the ANOVA-type test is a reasonable option if the monotone trend in genotypes g = 0, 1, and 2 is doubtful.

Cox model with a lasso penalty

In an analysis using SNP data, we may face a problem in which the number of SNPs exceeds the size of data, that is, mp, which frequently occurs even when a smaller number of SNPs are selected through a prescreening step. This may lead to a serious collinearity problem when directly applying the partial likelihood estimation to the Cox model. To address this problem, Tibshirani[24] estimates the parameters of the Cox model under the L1 constraint as follows:
β ̂ = arg max β , s l ( β ) , subject to j = 1 m | β j | s ,

where l(·) is the partial likelihood function [19].

The above optimization problem is suitable for reducing the dimension of covariates but is computationally difficult because the L1 objective function is not differentiable. To address this computational problem, previous studies have proposed many algorithms [13, 24-26]. Tibshirani[24] proposes an algorithm using quadratic programming within an iterative procedure. Gui and Li[25] propose an LAS-Cox procedure applying the Choleski decomposition and the LARS procedure. However, these algorithms can be computationally burdensome and sometimes fail to converge to an optimum because they involve quadratic programming and/or matrix inversions. Sohn et al. [13] propose glcoxph for the Cox model by using the gradient lasso algorithm in [27]. This glcoxph employs a coordinate-wise gradient decent with a deletion step and requires only univariate optimization in each iteration. Its convergence speed is almost independent of the number of input variables, and it does not require a matrix inversion, which makes it scalable to high-dimensional data and allows it to converge to a global optimum faster. glmpath [26] provides the entire penalization path for the Cox model in a forward stagewise manner. Because it requires matrix inversions only for active sets, it is faster and more stable than other methods. Sohn et al. [13] provided a comparative analysis using real and simulated data and show that the gradient lasso algorithm outperforms glmpath in analyzing high-dimensional survival data in terms of the sparsity, predictability, and computational efficiency of the final prediction model. Therefore, the following gradient lasso algorithm can be a useful alternative for fitting the Cox model to predict the survival time of patients based on high-dimensional SNP data:
  1. 1.

    Initialize: β=0 and k=0.

     
  2. 2.
    Do until convergence
    1. (a)
      Addition:
      1. (i)

        Compute the gradient l(β).

         
      2. (ii)

        Find the γ j maximizing | l(β)/ β j | for j=1,…,p and γ ̂ = s × sign ( ∂l ( β ) / β ĵ ) .

         
      3. (iii)

        Let v be a p-dimensional vector such that its γ j -th element γ ̂ and other elements are zeros.

         
      4. (iv)

        Find α ̂ = arg min α [ 0 , 1 ] l ( 1 α ) β + α v .

         
      5. (v)

        Update β = ( 1 α ̂ ) β + α ̂ v .

         
       
    2. (b)
      Deletion:
      1. (i)

        Calculate h σ =−l(β σ )+θ σ l(β σ ) T θ σ /|σ|, where σ={j:β j ≠0}.

         
      2. (ii)

        Find δ ̂ = arg min δ [ 0 , U ] l ( β + δ h ) , where h = h σ 0 and U= minkσ{−β k /h k :β k h k <0}.

         
      3. (iii)

        Update β = β + δ ̂ h .

         
       
    3. (c)

      Set m=m+1.

       
     
  3. 3.

    Return β.

     

Proposed algorithm for predicting a survival trait

We propose a new algorithm for fitting a Cox regression model using SNP data. The proposed algorithm consists of the following four steps: We (i) select significant SNPs by the MaxTest, as in Section “Example using real data”, (ii) convert these SNPs into corresponding scores by genetic models identified by the MaxTest, (iii) standardize these scores, and (iv) apply the gradient lasso algorithm [13] to selected SNPs. We summarize the algorithm in greater detail as follows:
  1. 1.

    Read in the clinical data {(X i ,δ i ),i=1,...,n} and SNP data {(si1,...,s i m ),i=1,...,n}, where s i j denotes the number of B alleles for SNP j (=1,...,m).

     
  2. 2.
    For SNP j (=1,...,m), calculate the variance and covarince matrix Σ ̂ j , and generate the null distribution of the MaxTest as follows.
    1. (a)

      For b=1,...,B (=100,000, say), generate ( t 1 j ( b ) , t 2 j ( b ) , t 3 j ( b ) ) from N ( 0 , Σ ̂ j ) .

       
    2. (b)

      Let q j ( b ) = max ( | t 1 j ( b ) | , | t 2 j ( b ) | , | t 3 j ( b ) | ) for b=1,...,B.

       
     
  3. 3.
    For SNP j (=1,...,m),
    1. (a)

      Using original data, calculate the test statistics (T 1j,T 2j,T 3j), the MaxTest statistic q j = max(|T 1j|,|T 2j|,|T 3j|), and two-sided p-values p 1j,p 2j,p 3j from the marginal test for respective genetic models.

       
    2. (b)
      Approximate the p-value of the MaxTest by
      p j = B 1 b = 1 B I ( q j ( b ) q j )
       
     
  4. 4.

    SNP screening: Select J (<<m) SNPs with p j <α for specified a α (=0.01, say).

     
  5. 5.

    For selected SNPs j (=1,...,J), identify the genetic model (1, 2, 3) by the lowest marginal p-value from p1j,p2j,p3j or the largest test statistic from T1j,T2j,T3j.

     
  6. 6.

    For patient i (=1,...,n), define covariates (zi1,...,z i J ) by the identified genetic model and the corresponding score.

     
  7. 7.
    Standardize the covariates:
    z ij = z ij z ̄ j s j ,

    where z ̄ j = n 1 i = 1 n z ij and s j 2 = n 1 i = 1 n ( z ij z ̄ j ) 2 .

     
  8. 8.

    Apply the gradient lasso to the Cox regression model with response data {(X i ,δ i ),i=1,...,n) and standardized covariates { ( z i 1 , ... , z iJ ) , i = 1 , ... , n } .

     

Results and discussion

Simulation study

We provide a simulation study. The data generation scheme is as follows: We generate SNP data z1,...,z m from N(0,1) random variables with an AR(1) correlation structure with the autocorrelation coefficient ρ(≥0), x1,...,x m . Due to linkage disequilibrium, SNPs which lay in close vicinity within chromosomes tend to have a stronger association. In this sense, an AR(1) correlation structure is a reasonable correlation structure for the continuous random variables generating SNP data. Let x1=ε1 and x j = ρ x j 1 + 1 ρ 2 ε j for j=2,...,m, where ε1,...,ε m IIDN(0,1) random numbers. The cutoff values for x j for generating z j determine allele frequency. For each SNP, let f1,f2,f3 (f1+f2+f3=1) denote the frequency of AA, AB, and BB genotypes, respectively, where B denotes the risk allele. Note that marginally x j N(0,1). The true model for the survival times is given as
Λ ( t ) = Λ 0 ( t ) exp j = 1 D β j z ij ,

where D denotes the number of prognostic SNPs.

For the experiment, we set m=1000, n=200, D=6, ρ=0 or 0.3, β j =0.8 (j=1,...,D), and a uniform censoring distribution for 15% or 30% of censoring. All six prognostic SNPs have (f1,f2,f3)=(.25,.5,.25). SNP 1 and SNP 4 have a dominant model; SNP 2 and SNP 5, a recessive model; and SNP 3 and SNP 6, a multiplicative model. Each of the remaining 994 SNPs has (AA,AB,BB) with (f1,f2,f3)=(1/3,1/3,1/3).

To evaluate the performance of the proposed method, we generate 200 random samples and divide them into a training set (100 samples) and a test set (100 samples). We calculate the MaxTest p-value of each SNP by using B=100,000 permutations from the training set and identify the genetic model for each SNP. We select SNPs with p-values less than α=0.01 and convert selected SNPs into corresponding scores by their genetic models. We apply the gradient lasso to the selected SNPs to fit the prediction model. Let SNPs j (=1,...,K) be included in the fitted prediction model with corresponding regression estimates β ̂ 1 , ... , β ̂ K . Then we can define the risk score for sample i as r i = β ̂ 1 z i 1 + + β ̂ K z iK . Using the median risk score from the test set as a cutoff value, we divide the patients in the test set into high- and low-risk groups. We apply a two-sample log-rank test to compare the survival distribution between these two risk groups. We repeat this procedure 100 times and count the number of SNPs and that of prognostic SNPs included in each fitted prediction model by the gradient lasso. We summarize the distribution of log-rank p-values from the test set, and for comparison purposes, we consider the prediction methods by assuming that all m SNPs have the same genetic model.

Table 1 reports the mean number of SNPs and that of prognostic SNPs included in the fitted prediction model, recovery rate, and the means (and standard deviations) of the log-rank p-value from the test set for the proposed method and the methods assuming a recessive, dominant, or multiplicative model for all SNPs under various simulation settings. We define recovery rate as the ratio of mean number of selected prognostic SNP to the mean number of selected SNP as in Sohn et al. [13]. The proposed method tends to result in prediction models with a smaller number of SNPs but a larger number of prognostic SNPs than the approaches assuming a specific genetic model for all SNPs (i.e., recessive, dominant, and multiplicative methods in the table). The recovery rates of the proposed method are higher than those of the methods based on a pre-specified model (recessive, dominant, and multiplicative). Among the three methods assuming a specific genetic model for all SNPs, the one assuming a multiplicative model shows the best performance in terms of the number of prognostic SNPs included in the final prediction model. In addition, the proposed method outperforms the recessive, dominant, and multiplicative methods in terms of the log-rank p-value and results in fitted prediction models with a smaller number of SNPs but a larger number of prognostic SNPs with 15% compared to 30% censoring. According to sample size (n) and the effect size (β), the mean number of SNPs and that of prognostic SNPs selected by the proposed method at ρ=0 and 30% censoring is shown in Table 2. The mean number of prognostic SNPs a little bit increases as β increase and the mean number of prognostic SNPs increases as n increases. The recovery rate increases as β or n increases.
Table 1

Mean numbers of SNPs and prognostic SNPs included in fitted prediction models, recovery rate and means/standard deviations of the log-rank p-value from test sets for the proposed method and methods assuming recessive, dominant, or multiplicative models for all SNPs

Censoring

ρ

Genetic

Mean number

Mean number of

Recovery

Mean (SD) p-value

  

model

of selected

of selected

rate

of the log-rank

   

SNPs

prognostic SNPs

 

test

30%

0

Proposed

6.72

5.05

0.75

<0.0001 (<0.0001)

  

Recessive

8.03

4.01

0.50

0.0052 (0.0018)

  

Dominant

6.66

3.85

0.58

<0.0001 (<0.0001)

  

Multiplicative

7.72

4.95

0.64

0.0004 (0.0003)

 

0.3

Proposed

6.51

4.83

0.74

0.0001 (0.0001)

  

Recessive

7.73

3.83

0.50

0.0045 (0.0016)

  

Dominant

6.58

3.66

0.56

0.0011 (0.0007)

  

Multiplicative

7.52

4.72

0.63

0.0006 (0.0004)

15%

0

Proposed

6.65

5.18

0.78

<0.0001 (<0.0001)

  

Recessive

8.59

4.19

0.49

0.0028 (0.0011)

  

Dominant

6.69

3.88

0.58

<0.0001 (<0.0001)

  

Multiplicative

7.96

4.98

0.63

0.0005 (0.0005)

 

0.3

Proposed

6.37

4.98

0.78

<0.0001 (<0.0001)

  

Recessive

7.88

3.94

0.50

0.0048 (0.0028)

  

Dominant

6.38

3.74

0.59

0.0011 (0.0011)

  

Multiplicative

7.55

4.89

0.65

0.0001 (<0.0001)

Table 2

Mean number of SNPs and prognostic SNPs included in the fitted prediction models, recovery rate and means/standard deviations of the log-rank p-values from the test set for the proposed method at ρ = 0 and censoring = 30%

n

β

Mean number of

Mean number of

Recovery rate

Mean (SD) p-value

  

selected SNP

selected prognostic SNP

 

of the log-rank test

200

0.8

6.72

5.05

0.75

<0.0001 (<0.0001)

 

1

6.13

5.18

0.85

<0.0001 (<0.0001)

 

2

5.60

5.17

0.92

<0.0001 (<0.0001)

300

0.8

6.18

5.53

0.89

<0.0001 (<0.0001)

400

0.8

5.89

5.72

0.97

<0.0001 (<0.0001)

Example using real data

We apply the proposed method to the GWAS data in Choi et al. [28], who provide a GWAS of 119 patients with normal karyotype acute myeloid leukemia (AML-NK) by using Affymetric Genome-Wide Human SNP Arrays 6.0 (San Diego, CA, USA). We exclude those SNPs with missing genotype data for any patient. We also exclude those SNPs with only one genotype for the 119 patients. The final data set for the analysis includes m = 251, 748 autosomal SNPs from n = 119 patients. The primary endpoint in this analysis is event-free survival (EFS), which is defined as the interval between the registration and the end of induction chemotherapy for patients showing no complete response (CR), a relapse after achieving a CR to induction chemotherapy, or death.

We employ the leave-one-out cross-validation (LOOCV) procedure to evaluate the predictive performance of the proposed method for the data set. From a training set of size n−1 = 118, we calculate the MaxTest p-value of each SNP based on B=100,000 permutations, select J candidate SNPs with p-values less than α=0.01 by MaxTest, and apply the gradient lasso to candidate SNPs to obtain a prediction model. Using the median risk score for the patients in the training set, we allocate those patients who are left out for the validation to the high- or low-risk group. We repeat this procedure n times and calculate the log-rank p-value to compare the EFS between the two risk groups. Figure 1(a) shows the Kaplan-Meier curves for the high- and low-risk groups classified by the LOOCV procedure. The five-year EFS rate for the low-risk group (n=60, 53.8%) is much higher than that for the high-risk group (n=59, 32.9%) with the estimated hazard ratio of 0.446 (95 % CI, 0.256-0.778), and the log-rank p-value is 0.0035.
https://static-content.springer.com/image/art%3A10.1186%2F1471-2105-14-58/MediaObjects/12859_2012_Article_5866_Fig1_HTML.jpg
Figure 1

Kaplan-Meier curves for high- and low-risk groups classified by the LOOCV procedure.

A standard approach may be to fit a prediction model assuming a multiplicative genetic models for all SNPs, e.g. Tan et al. [29]. We analyzed this data set using the same method as above except that all SNPs were assumed to have a multiplicative model. Figure 1(b) displays the LOOCV results. Note that the fitted prediction models do not significantly partition the test set into high- and low-risk groups by ignoring the possible genetic models.

We also apply our prediction procedure to the whole data set with n=119. Using α=0.01, we select J=1122 candidate SNPs, among which 444 (39.6%) are shown to have a recessive model, 463 (41.3%) a dominant model, and 215 (19.2%) a multiplicative model. By applying the gradient lasso to the selected 1122 SNPs, we obtain the final prediction model including k=24 SNPs. Table 3 lists the RS IDs, the chromosome numbers, the base-pair position and the gene name of the 24 SNPs included in the final prediction model. For each of the 24 SNPs, we report the genetic model (=1 for recessive model, =2 for dominant model, and =3 for multiplicative model) identified by the MaxTest, the marginal MaxTest p-value and number of times (frequency) that each SNP is included in the prediction models during the LOOCV. Note that the first four SNPs in Table 2 are included in all 119 prediction models during LOOCV.
Table 3

List of 24 SNPs selected by the proposed method from the whole data set of 119 samples, their MaxTest p-values, genetic models, the number of times selected by prediction models fitted during the LOOCV procedure

RS ID

Chr

Position

Gene name

Genetic

P-value

Frequency

    

model g

  

rs1030254

16

60696651

LOC644649, CDH8, LOC729159

3

0.00009

119

rs1030252

16

60696869

LOC644649, CDH8, LOC729159

2

0.00010

119

rs10798122

1

187584699

PLA2G4A, FAM5C

1

0.00048

119

rs10026207

4

186039201

HELT, SLC25A4

3

0.00233

119

rs13333329

16

1695776

CRAMP1L

3

0.00015

117

rs2132183

3

84966867

LOC440970,CADM2

3

0.00149

117

rs1950400

14

27105035

MIR4307,NOVA1

2

0.00040

115

rs2155777

11

133290007

OPCML

3

0.00142

113

rs1677914

12

78274425

NAV3

2

0.00283

106

rs1476847

18

9834599

RAB31

1

0.00029

102

rs7614596

3

84986027

LOC440970,CADM2

2

0.00020

100

rs2648117

4

186787096

SORBS2

3

0.00856

90

rs1851317

15

35077786

GJD2,ACTC1

1

0.00999

88

rs3790217

20

19441650

SLC24A3

2

0.00728

85

rs4902990

14

72618432

RGS6

2

0.00004

81

rs9482583

6

125318379

RNF217

3

0.00847

79

rs3020444

14

64791013

ESR2

3

0.00288

77

rs10851869

15

74331083

PML

2

0.00036

65

rs11986200

8

22698209

PEBP4

1

0.00222

63

rs11260756

1

16759616

SPATA21

1

0.00827

63

rs4968415

17

60264240

MED13,TBC1D3P2

1

0.00075

62

rs12416722

11

133300460

OPCML

1

0.00067

59

rs626266

12

72888187

TRHDE

2

0.00070

52

rs16852300

2

167414424

SCN7A,XIRP2

3

0.00513

33

The RGS6 gene (rs4902990) is associated with treatment outcomes in AML-NK patients. RGS6, a regulator of G-protein signaling 6, modulates the G-protein function in the signaling pathway by activating the intrinsic GTPase activity of alpha subunits [30, 31]. An SNP on RGS6 has been found to modulate the risk of bladder cancer [32]. In addition, it is known that RGS6 induces apoptosis through a mitochondrial-dependent pathway, which implies that RGS6 may be involved in cancer progression [29]. Further, membrane drug transporters, including SLC25A4 (rs10026207) and SLC24A3 (rs3790217), are known to be associated with event-free survival. SLC25A4, solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator; ANT1), member 4, is known to interact with the Bcl-2-associated X protein, which is involved in the apoptosis pathway [33, 34]. The rs10798122 SNP on family with sequence similarity 5, member C, FAM5C, is selected by the proposed model. A loss of hypermethylated FAM5c is known to be associated with the development of tongue squamous cell carcinoma or gastric cancer [35, 36].

Conclusions

We have proposed a prediction method for a survival endpoint using SNPs. The paper also proposes a MaxTest to screen out nonprognostic SNPs and identify genetic model of prognostic SNPs. The simulation results indicate substantial prognostic power for the proposed prediction method. Noteworthy is that, in conjunction with the MaxTest, the proposed method provides more parsimonious prediction models with more prognostic SNPs than those prediction methods ignoring the true genetic model of prognostic SNPs. We apply real GWAS data to patients with acute myeloid leukemia and find that the proposed method provides a prediction model that can efficiently classify the patients into high- and low-risk groups by using a small number of SNPs that are known to be biologically informative. Although the proposed method is limited to the prediction of time-to-event traits, it can be easily extended to a wide range of traits, including dichotomous or continuous ones.

Notes

Declarations

Acknowledgements

This research was supported by a grant from the National Cancer Institute, CA142538.

Authors’ Affiliations

(1)
Department of Statistics and Information Science, Dongguk University
(2)
Samsung Cancer Research Institute, Samsung Medical Center
(3)
In Vitro Diagnostics Lab., Bio Research Center, Samsung Advanced Institute of Technology
(4)
Department of Medical Oncology and Hematology, Princess Margaret Hospital, University of Toronto
(5)
Department of Biostatistics and Bioinformatics, Duke University

References

  1. Chen BE, Sakoda LC, Hsing AW, Rosenberg PS: Resampling-based multiple hypothesis testing procedures for genetic case-control association studies. Genet Epidemiol. 2006, 30 (6): 495-507. 10.1002/gepi.20162.View ArticlePubMedGoogle Scholar
  2. Gordon D, Finch SJ: Factors affecting statistical power in the detection of genetic association. J Clin Invest. 2005, 115 (6): 1408-1418. 10.1172/JCI24756.PubMed CentralView ArticlePubMedGoogle Scholar
  3. Hao K, Xu X, Laird N, Wang X, Xu X: Power estimation of multiple SNP association test of case-control study and application. Genet Epidemiol. 2004, 26 (1): 22-30. 10.1002/gepi.10293.View ArticlePubMedGoogle Scholar
  4. Skol AD, Scott LJ, Abecasis GR, Boehnke M: Joint analysis is more efficient than replication-based analysis for two-stage genome-wide association studies. Nat Genet. 2006, 38 (2): 209-213. 10.1038/ng1706.View ArticlePubMedGoogle Scholar
  5. Sluis SVD, Dolan CV, Neale MC, Posthuma D: Power calculations using exact data simulation: a useful tool for genetic study designs. Behav Genet. 2008, 38 (2): 202-211. 10.1007/s10519-007-9184-x.PubMed CentralView ArticlePubMedGoogle Scholar
  6. Westfall PH, Young SS: Resampling-based Multiple, Testing: Examples and Methods for Pvalue Adjustment. 1993, New York: WileyGoogle Scholar
  7. Storey JD: A direct approach to false discovery rates. J R Stat Soc, Ser B. 2002, 64: 479-498. 10.1111/1467-9868.00346.View ArticleGoogle Scholar
  8. Zheng G, Freidlin B, Gastwirth JL: Comparison of robust tests for genetic association using case-control studies. IMS Lecture Notes-Monograph Series 2nd Lehmann Symposium - Optimality. 2006, 49: 253-265.View ArticleGoogle Scholar
  9. Li Q, Zheng G, Li Z, Yu K: Efficient approximation of p-values of the maximum of correlated tests, with applications to genome-wide association studies. Ann Human Genet. 2008, 72: 397-406. 10.1111/j.1469-1809.2008.00437.x.View ArticleGoogle Scholar
  10. Bair E, Tibshirani R: Semi-supervised methods to predict patient survival from gene expression data. PLoS Biol. 2004, 2: 511-522.View ArticleGoogle Scholar
  11. Gui J, Li H: Penalized Cox regression analysis in the high-dimensional and low-sample size settings, with applications to microarray gene expression data. Bioinformatics. 2005, 21: 3001-3008. 10.1093/bioinformatics/bti422.View ArticlePubMedGoogle Scholar
  12. Kaderali L, Zander T, Faigle U, Wolf J, Schultze JL, Schrader R: CASPAR: a hierarchical Bayesian approach to predict survival times in cancer from gene expression data. Bioinformatics. 2006, 22: 1495-1502. 10.1093/bioinformatics/btl103.View ArticlePubMedGoogle Scholar
  13. Sohn I, Kim J, Jung SH, Park C: Gradient lasso for Cox proportional hazards model. Bioinformatics. 2009, 25: 1775-1781. 10.1093/bioinformatics/btp322.View ArticlePubMedGoogle Scholar
  14. Kooperberg C, LeBlanc M, Obenchain V: Risk Prediction Using Genome-Wide Association Studies. Genet Epidemiol. 2010, 34: 643-652. 10.1002/gepi.20509.PubMed CentralView ArticlePubMedGoogle Scholar
  15. Owzar K, Li Z, Cox N, Jung SH: Power and sample size calculations for SNP association Studies with censored time-to-event outcomes. Genet Epidemiol. 2012, 36: 538-548. 10.1002/gepi.21645.PubMed CentralView ArticlePubMedGoogle Scholar
  16. Conneely KN, Boehnke M: So many correlated tests, so little time! Rapid adjustment of p values for multiple correlated tests. American J Hum Genet. 2007, 81: 1158-1168. 10.1086/522036.View ArticleGoogle Scholar
  17. Li Q, Yu K, Li Z, Zheng G: Max-rank: a simple and robust genome-wide scan for case-control association studies. Hum Genet. 2008, 123 (6): 617-623. 10.1007/s00439-008-0514-8.View ArticlePubMedGoogle Scholar
  18. Hoggart CJ, Whittaker JC, De Iorio M, Balding DJ: Simultaneous analysis of all SNPs in genome-wide and re-sequencing association studies. PLoS Genet. 2008, 4: e1000130-10.1371/journal.pgen.1000130.PubMed CentralView ArticlePubMedGoogle Scholar
  19. Cox DR: Regression Models and Life Tables (with Discussion). J R Stat Soc, Ser B. 1972, 34: 187-220.Google Scholar
  20. Fleming TR, Harrington DP: Counting Processes and, Survival Analysis. 1991, New York: WileyGoogle Scholar
  21. Freidlin B, Zheng G, Li Z, Gastwirth JL: Trend tests for case-control studies of genetic markers: power, sample size and robustness. Hum Hered. 2002, 53 (3): 146-152. 10.1159/000064976.View ArticlePubMedGoogle Scholar
  22. Jung SH, Hui S: Sample size calculations to compare K different survival distributions. Lifetime Data Anal. 2002, 8: 361-373. 10.1023/A:1020518905233.View ArticlePubMedGoogle Scholar
  23. Jung SH, Owzar K, George SL: A multiple testing procedure to associate gene expression levels with survival. Stat Med. 2005, 24: 3077-3088. 10.1002/sim.2179.View ArticlePubMedGoogle Scholar
  24. Tibshirani R: The lasso method for variable selection in the Cox model. Stat Med. 1997, 16: 385-395. 10.1002/(SICI)1097-0258(19970228)16:4<385::AID-SIM380>3.0.CO;2-3.View ArticlePubMedGoogle Scholar
  25. Gui J, Li H: Penalized Cox regression analysis in the high-dimensional and low-sample size settings, with applications to microarray gene expression data. Bioinformatics. 2005, 21: 3001-3008. 10.1093/bioinformatics/bti422.View ArticlePubMedGoogle Scholar
  26. Park MY, Hastie T: L1 regularization path algorithm for generalized linear models. J R Stat Soc B. 2007, 69: 659-677. 10.1111/j.1467-9868.2007.00607.x.View ArticleGoogle Scholar
  27. Kim J, Kim Y, Kim Y: A gradient-based optimization algorithm for lasso. J Comput Graph Stat. 2008, 17: 994-1009. 10.1198/106186008X386210.View ArticleGoogle Scholar
  28. Choi H, Jung C, Kim S, Kim H-J, Kim T, Zhang Z, Shin E-S, Lee J-E, Sohn SK, Moon JH, Kim SH, Kim KH, Mun Y-C, Kim H, Park J, Kim J, Kim D, K: Genome-wide genotype-based risk model for survival in acute myeloid leukemia patients with normal karyotype. 2012, In submitionGoogle Scholar
  29. Tan XL, Moyer AM, Fridley BL, Schaid DJ, Niu N, Batzler AJ, Jenkins GD, Abo RP, Li L, Cunningham JM, Sun Z, Yang P, Wang L: Genetic variation predicting cisplatin cytotoxicity associated with overall survival in lung cancer patients receiving platinum-based chemotherapy. Clin Cancer Res. 2011, 17: 5801-5811. 10.1158/1078-0432.CCR-11-1133.PubMed CentralView ArticlePubMedGoogle Scholar
  30. Berman DM, Gilman AG: Mammalian RGS proteins: barbarians at the gate. J Biol Chem. 1998, 273 (3): 1269-1272. 10.1074/jbc.273.3.1269.View ArticlePubMedGoogle Scholar
  31. Maity B, Yang J, Huang J, Askeland RW, Bera S, Fisher RA: Regulator of G protein signaling 6 (RGS6) induces apoptosis via a mitochondrial-dependent pathway not involving its GTPase-activating protein activity. J Biol Chem. 2011, 286 (2): 1409-1419. 10.1074/jbc.M110.186700.PubMed CentralView ArticlePubMedGoogle Scholar
  32. Berman DM, Wang Y, Liu Z, Dong Q, Burke LA, Liotta LA, Fisher R, Wu X: A functional polymorphism in RGS6 modulates the risk of bladder cancer. Cancer Res. 2004, 64 (18): 6820-6826. 10.1158/0008-5472.CAN-04-1916.View ArticlePubMedGoogle Scholar
  33. Baines CP, Molkentin JD: Adenine nucleotide translocase-1 induces cardiomyocyte death through upregulation of the pro-apoptotic protein Bax. J Mol Cell Cardiol. 2009, 46 (6): 969-977. 10.1016/j.yjmcc.2009.01.016.PubMed CentralView ArticlePubMedGoogle Scholar
  34. Malorni W, Farrace MG, Matarrese P, Tinari A, Ciarlo L, Mousavi-Shafaei P, D’Eletto M, Di Giacomo G, Melino G, Palmieri L, Rodolfo C, Piacentini M: The adenine nucleotide translocator 1 acts as a type 2 transglutaminase substrate: implications for mitochondrial-dependent apoptosis. Cell Death Differ. 2009, 16 (11): 1480-1492. 10.1038/cdd.2009.100.View ArticlePubMedGoogle Scholar
  35. Chen L, Su L, Li J, Zheng Y, Yu B, Yu Y, Yan M, Gu Q, Zhu Z, Liu B: Hypermethylated FAM5C and MYLK in serum as diagnosis and pre-warning markers for gastric cancer. Dis Markers. 2012, 32 (3): 195-202.PubMed CentralView ArticlePubMedGoogle Scholar
  36. Kuroiwa T, Yamamoto N, Onda T, Shibahara T: Expression of the FAM5C in tongue squamous cell carcinoma. Oncol Rep. 2009, 22 (5): 1005-1011.PubMedGoogle Scholar

Copyright

© Kim et al.; licensee BioMed Central Ltd. 2013

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.